tiprankstipranks
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC

Fennec Pharmaceuticals Stock Analysis & Ratings

FENC Stock Chart & Stats

Day’s Range$5.1 - $5.74
52-Week Range$3.82 - $10.08
Previous Close$5.3
Volume22.31K
Average Volume (3M)43.68K
Market Cap$143.74M
P/E Ratio-8.3
Beta-0.07
Next EarningsAug 12, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-0.67


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

FENC FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $3.82 and its highest was $10.08 in the past 12 months.
    What is Fennec Pharmaceuticals’s market cap?
    Fennec Pharmaceuticals’s market cap is $143.74M.
      What is Fennec Pharmaceuticals’s price target?
      The average price target for Fennec Pharmaceuticals is $10.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $10.00 ,the lowest forecast is $10.00. The average price target represents 81.16% Increase from the current price of $5.52.
        What do analysts say about Fennec Pharmaceuticals?
        Fennec Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Fennec Pharmaceuticals’s upcoming earnings report date?
          Fennec Pharmaceuticals’s upcoming earnings report date is Aug 12, 2022 which is in 88 days.
            How were Fennec Pharmaceuticals’s earnings last quarter?
            Fennec Pharmaceuticals released its earnings results on May 12, 2022. The company reported -$0.14 earnings per share for the quarter, the consensus estimate of -$0.14 by $0.
              Is Fennec Pharmaceuticals overvalued?
              According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
                Does Fennec Pharmaceuticals pay dividends?
                Fennec Pharmaceuticals does not currently pay dividends.
                What is Fennec Pharmaceuticals’s EPS estimate?
                Fennec Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Fennec Pharmaceuticals have?
                Fennec Pharmaceuticals has 26,040,000 shares outstanding.
                  What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
                  Fennec Pharmaceuticals reported an EPS of -$0.14 in its last earnings report, expectations of -$0.14. Following the earnings report the stock price went up 2.515%.
                    Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
                    Currently, no hedge funds are holding shares in FENC

                    ---

                    Fennec Pharmaceuticals Stock Analysis

                    The Fennec Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Fennec Pharmaceuticals

                    Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Eiger Biopharmaceuticals
                    scPharmaceuticals
                    Aeglea Biotherapeutics
                    Synlogic
                    Erytech Pharma SA

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis